Trials / Completed
CompletedNCT00407225
Study of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation
Phase 2a Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation After Cataract Surgery
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (planned)
- Sponsor
- Sirion Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 12 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this phase 2 study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of postoperative inflammation.
Detailed description
The objective is to assess the efficacy and safety of 0.002% and 0.05% difluprednate ophthalmic emulsions in patients with postoperative inflammation after cataract surgery (implantation of intraocular lens). In addition, the evaluation system for a future dose-finding phase III study of difluprednate ophthalmic emulsion will be established.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Difluprednate Ophthalmic Emulsion |
Timeline
- Start date
- 1999-12-01
- Completion
- 2000-10-01
- First posted
- 2006-12-04
- Last updated
- 2006-12-06
Source: ClinicalTrials.gov record NCT00407225. Inclusion in this directory is not an endorsement.